William Rosellini(born July 11, 1979) is a former professional baseball player, scientist, inventor, and entrepreneur. Rosellini was the first employee and is the current President of CytoImmune Therapeutics, Inc. CytoImmune is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. Previously, he co-invented the platform technology for Vivistim®, an implantable device that was FDA-approved for stroke rehabilitation, and was the founding CEO of Microtransponder, Inc., the company that is commercializing the technology. He has previously taken Perimeter Medical Imaging AI, Inc. public in Canada and Nexeon Medsystems, Inc. public in the US. He has previously testified to Congress on neurotechnologies. Rosellini is a former minor league pitcher with Arizona Diamondbacks.
Early life and education
Rosellini played for Team USA in the 1994 and 1997 Junior Olympics. He attended Vanderbilt University on a full athletic scholarship and was drafted in the 16th round of MLB draft. He holds a B.A. in Economics from the University of Dallas; an M.S. in Accounting, an MBA, and an M.S. in Accounting from the University of Texas at Dallas; a Juris Doctor from Hofstra Law; an M.S. in Regulatory Science from the University of Southern California; an M.S. in Computational Biology from a joint program at Rutgers and New Jersey Institute of Technology, and completed coursework at Rice in the Nanoscale Physics program and submitted his written dissertation but did not defend his Ph.D., receiving his Master’s in Neuroscience from the University of Texas at Dallas in Neuroscience.
Rosellini is currently the President of CytoImmune Therapeutics, Inc, a clinical-stage biotechnology company. The Company is developing proprietary Chimeric Antigen Receptor (CAR) engineered NK cells (CAR-NK™) technology, which we licensed from the laboratories of Drs. Michael Caligiuri and Jianhua Yu at the City of Hope National Medical Center (COH).
He started his career in 2005, co-founding MicroTransponder Inc., the company initially set out to develop tiny, implantable, wireless “neurotransponders” that may open the way to substantial miniaturization of neurostimulation devices but during a series of animal experiments conducted in Michael Kilgard’s neuroplasticity lab, they learned they could generate specific neural plasticity in the brain that could be used to treat disorders such as tinnitus, chronic orofacial pain, anxiety, and stroke-induced functional impairments. The company has received FDA approval for its Vivistim®, the first FDA-approved neurostimulation device to pair vagus nerve stimulation with stroke rehabilitation therapy. This pairing helps strengthen the brain connections needed to improve hand and arm function. It’s the only system of its kind, and it is proven safe and effective. Rosellini left his position as CEO at Microtransponder in 2012 after temporarily losing his voice to thyroid cancer.
After Microtransponder, Rosellini formed Nexeon Medsystems, Inc. and took it public (OTC:QB NXXN) to develop additional neurostimulation products. The company garnered CE Mark approval for its closed-loop deep brain stimulation and acquired Medi-Line, a Belgian medical device manufacturer. The company was unable to raise funding to pursue the commercialization of the device and wound-down operations in 2019.
Rosellini was named the CEO of Perimeter Medical, Inc. (TSX:V "PINK") Perimeter developed and commercialized a medical imaging device that utilized machine learning to transform cancer surgery. He oversaw their first US commercial launch and took the company public via the TSX.V as PINK. The company’s ticker symbol, “PINK” is a reference to the pink ribbons displayed during Breast Cancer Awareness Month.
Scientific Video Game Consultant Rosellini was a scientific consultant on the Deus Ex Human Revolutions video game series that depicts the conflict between natural humans and augmented humans having electronic body parts. He was the science consultant on the Deux Ex: Human Revolution and Deus Ex: Mankind Divided for six years. He gave TED talk in 2016 to describe how medical advancements will make bodies more like cars with replaceable, programmable, and more intelligent implants.
Congressional Testimony Rosellini testified to U.S. Congress on the importance of non-dilutive funding for inventors and researchers.
Rosellini has published peer-reviewed articles in the field of bioinformatics and databases. Some of his research articles include:
A SU-8-Based Fully Integrated Biocompatible, Inductively Powered Wireless Neurostimulator Willingness to Accept and Pay for Implantable Tinnitus Treatments: A Survey Wireless peripheral nerve stimulation increases pain threshold in two neuropathic rat models. A Voltage-Controlled Capacitive Discharge Method for Electrical Activation of Peripheral Nerves Neuroprosthetics and Medicare Reimbursement The United States Database Debate – Proteins as virtual property
Awards and recognition
O'Donnell Award finalist, Academy of Medicine, Engineering and Science, 2012 40 Under Forty honoree, 2011 Tech Titans Awards finalist, The Metroplex Technology Business Council (MTBC), 2010 Entrepreneur of the Year, 2010 2009 Graduate Student Entrepreneur of the Year, Entrepreneurs Organization at the Global Student Entrepreneur Awards (GSEA)